The loss of REGENXBIO under GAAP for 9 months of 2020 amounted to $65.009 million, which is 4.8% lower compared to $68.269 million in the previous year. Revenue increased 5.6 times to $133.122 million compared to $23.465 million a year earlier.
The loss of REGENXBIO under GAAP for 9 months of 2020 amounted to $65.009 million, which is 4.8% lower compared to $68.269 million in the previous year. Revenue increased 5.6 times to $133.122 million compared to $23.465 million a year earlier. 
regenxbio.gcs-web.com
English (US) 